• Epidemiological studies and clinical trials in urology and chronic kidney disease
• Strategy
development for designing national programs to prevent and treat
chronic diseases (chronic kidney disease, non-malignant urologic
conditions, lung and respiratory diseases)
• Program evaluation of treatment interventions (design, analysis and interpretation of randomized clinical trials)
• Design, analysis and interpretation of population-based studies (observational epidemiologic studies).
Program management and scientific involvement with the following studies either solely or in collaboration with Division staff:
• The Folic Acid for Vascular Outcome Reduction (FAVORIT) Trial
• The Dialysis Access Consortium (DAC)
• The Program to Reduce Incontinence by Diet and Exercise (PRIDE)
• The Boston Area Community Health (BACH) Survey
• The Chronic Renal Insufficiency Cohort (CRIC) Study
• The Urinary Incontinence treatment (UITN) Network
• The Interstitial Cystitis Clinical Research Network (ICCRN)
• The Chronic Prostatitis Collaborative Research Network (CPCRN)
• The Chronic Kidney Disease (CKD) Epidemiology Project
• The Minimally Invasive Surgical Therapy (MIST) Consortium
• The Complementary and Alternative Medicine for Urological Symptoms
(CAMUS)
• The Oral versus IV iron trial
• The African American Study of Kidney Disease and Hypertension (AASK)
Cohort Study
• The Clinical Trial of Alpha-Blocker for Patients with Urinary Tract Stones (STONE Study)
1979 Ph.D., University of Michigan, Ann Arbor, Michigan
1979-1983: Faculty, Department of Epidemiology and Biometry, School of Public Health, University of Illinois, Chicago, Illinois
1983-1989: Division of Lung Diseases, National Heart, Lung, and Blood Institute
1989 to present: Division of Kidney, Urologic, and Hematologic Diseases, NIDDK